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See related article on page 155. Recent evidence supports the sodium-hydrogen antiport system as animportant player in the pathophysiology of myocardial ischemia-reperfusion injury.1-3 Accumulation of hydrogen ions in the myo-cyte cytosol during ischemia creates a proton gradient that pro-motes the efflux of hydrogen ions in exchange for the influx ofsodium ions. This hydrogen ion–driven process may be self-lim-
iting during ischemia because the hydrogen ion gradient is blunted by the accumu-
lation of H in the interstitial (extracellular) compartment, and extracellular acidosis
and accumulation of acid products attenuates activity of the exchanger.3 However,
reactivation of the antiport mechanism during early reperfusion leads to a reactiva-
tion of the exchange system. The buildup of intracellular sodium secondarily
activates the Na-Ca2 exchange mechanism to operate in the reverse mode,
resulting in a net calcium accumulation. The intracellular Ca2 accumulation is
thought to be the event that leads to dysfunction and cell death. Therefore, re-
alkalinization of intracellular pH by the sodium-hydrogen exchange system and
subsequent reversal of the sodium-calcium exchange system favoring net calcium
accumulation work in concert to cause cell injury during ischemia and/or reperfu-
sion.
Inhibition of the sodium-hydrogen exchange mechanism during ischemia (ie,
before treatment) has been reported to reduce infarct size, degree of contracture, and
arrhythmias in experimental coronary artery occlusion studies, reduce edema in
postischemic myocardium, and restore systolic function in isolated perfused heart
models.1 Inhibition of the antiporter may be more effective than ischemic precon-
ditioning.4 Furthermore, studies in which inhibitors of the sodium-hydrogen anti-
porter were used as adjuncts to cardioplegia showed greater myocardial protection
than unsupplemented cardioplegic solutions.5,6 Inhibition of the sodium-hydrogen
exchanger during ischemia, and to some (inconsistent) extent during reperfusion,
was a cardioprotective strategy that showed promise. The GUARDIAN trial con-
firmed the cardioprotective potential of the sodium-hydrogen exchange inhibitor
cariporide in patients undergoing coronary artery bypass graft surgery, in which
there was a 23% risk reduction with the higher dose of cariporide (120 mg tid). The
benefits of cariporide in cardiac surgery is the subject of another multicenter clinical
trial, the EXPEDITION trial.
In this issue of the Journal, Muraki and associates7 evaluated the cardioprotec-
tion of cariporide (HOE 642) as an adjunct to blood cardioplegia in an experimental
model that simulates surgical revascularization of evolving infarction. The authors
chose a 10-fold higher concentration of cariporide than used in other studies, a
concentration that did not inhibit neutrophil oxidant generation and degranulation.
The authors found that this concentration of cariporide used as an adjunct to blood
cardioplegia reduced infarct size (ie, decreased morphologic injury to severely
injured myocardium), preserved postcardioplegic function of coronary artery endo-
thelium from the area at risk, and attenuated neutrophil accumulation in the
reperfused myocardium.
The protocol in the study by Muraki and associates differs from that used in the
GUARDIAN clinical trial. In this clinical trial, cariporide was given intravenously
preoperatively and postoperatively over a range of 2 to 7 days. The results of
Muraki’s group suggest that a shorter period of delivery of cariporide is beneficial,
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albeit at a higher concentration. However, further studies
are required to determine whether these results represent
optimal protection using the strategy of inhibiting the sodi-
um-hydrogen antiporter. For example, pretreatment before
cardiopulmonary bypass may be tested to determine
whether greater degree of protection could be obtained than
that observed with cariporide as an adjunct solely to car-
dioplegia. Additionally, the additional benefits of intrave-
nous administration of cariporide concomitant with cardio-
plegia and subsequent reperfusion would be consistent with
the data from some studies that inhibition of the antiporter
during reperfusion is also an effective strategy in preventing
ischemia-reperfusion injury. Last, although the sodium-hy-
drogen antiporter is active at hypothermic temperatures, the
efficacy of inhibitors should be examined in other modali-
ties of cardioplegia, such as warm induction, tepid and
warm cardioplegia temperatures.
The concentration of cariporide used (10 mol/L) by
Muraki and associates did not alter neutrophil oxidant ac-
tivity and degranulation. However, treatment with caripo-
ride-enhanced blood cardioplegia attenuated the accumula-
tion of neutrophils in the reperfused area at risk
myocardium, ostensibly by inhibiting the local neutrophil-
mediated inflammatory response to ischemia-reperfusion,
rather than by a direct effect. The data for a significant
contribution of neutrophils and other inflammatory cells and
cytokines to postischemic injury is convincing.
This makes a compelling case for a multi-strategy ap-
proach to myocardial protection, and underscores the phi-
losophy that there is no single magic bullet that will adequately
address the complex, multi-pathway pathophysiology of isch-
emia-reperfusion injury. Increasing the concentration of cari-
poride or other sodium-hydrogen exchange inhibitors to di-
rectly inhibit neutrophils may express the toxic effects of these
inhibitors. On the other hand, inhibitors of the sodium-hydro-
gen antiporter can be combined with other specific strategies
that deplete leukocytes and inhibit neutrophil function, such as
neutrophil filters,6 nitric oxide or adenosine.8
The concept of cardioprotection using inhibitors of the
sodium-hydrogen antiporter can be expanded to include a
number of other scenarios: (1) attenuation of multi-organ
injury, particularly cerebral injury during circulatory arrest;
(2) protection of the spinal cord during abdominal aortic
repair; (3) protection during off-pump coronary artery by-
pass surgery. Although there is a paucity of compelling data
that the myocardium subtended by the target coronary artery
is injured by transient and brief “elective” occlusions, this
area of investigation is fertile ground. (4) Finally, and less
related to cardiac surgery per se, the use of sodium-hydro-
gen exchange inhibitors during percutaneous coronary in-
terventions can be further investigated. The clinical study by
Rupprecht and colleagues9 has provided a proof of concept
that systemic administration of a sodium-hydrogen ex-
change inhibitor reduces clinical end points of cardiac in-
jury. A localized intracoronary approach to the delivery of
therapy may potentially provide cardioprotection by allow-
ing higher concentrations necessary to target neutrophil
function to be delivered, without the threat of systemic
accumulation and toxicity. The present report by Muraki
and associates is an excellent reference for the investigators
working in this area of research.
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